Carret Asset Management LLC Sells 134 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Carret Asset Management LLC trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 7,842 shares of the medical research company’s stock after selling 134 shares during the period. Carret Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $4,162,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. WCM Investment Management LLC increased its holdings in Thermo Fisher Scientific by 0.3% during the 4th quarter. WCM Investment Management LLC now owns 989,837 shares of the medical research company’s stock worth $527,524,000 after purchasing an additional 2,928 shares during the period. Phoenix Holdings Ltd. increased its holdings in Thermo Fisher Scientific by 21.4% during the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after purchasing an additional 1,654 shares during the period. DMC Group LLC increased its holdings in Thermo Fisher Scientific by 16.5% during the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after purchasing an additional 84 shares during the period. S. R. Schill & Associates increased its holdings in shares of Thermo Fisher Scientific by 106.3% in the 4th quarter. S. R. Schill & Associates now owns 1,537 shares of the medical research company’s stock valued at $816,000 after acquiring an additional 792 shares during the period. Finally, Check Capital Management Inc. CA purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter valued at $219,000. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 0.5 %

TMO traded up $3.03 during trading hours on Wednesday, reaching $577.62. The company’s stock had a trading volume of 2,034,882 shares, compared to its average volume of 1,567,231. Thermo Fisher Scientific Inc. has a fifty-two week low of $415.60 and a fifty-two week high of $603.82. The stock has a market cap of $220.48 billion, a PE ratio of 37.39, a P/E/G ratio of 2.31 and a beta of 0.80. The business’s 50-day moving average is $572.03 and its 200-day moving average is $528.72. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.75 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating analysts’ consensus estimates of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The firm had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. During the same period in the prior year, the firm posted $5.40 earnings per share. The firm’s quarterly revenue was down 4.9% on a year-over-year basis. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 21.51 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.10%.

Insider Transactions at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total transaction of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a document filed with the SEC, which is available at this link. In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, March 12th. The stock was sold at an average price of $597.98, for a total value of $5,979,800.00. Following the completion of the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $74,039,491.68. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the sale, the senior vice president now owns 12,901 shares in the company, valued at $7,250,362. The disclosure for this sale can be found here. Insiders sold a total of 50,277 shares of company stock worth $28,513,384 over the last ninety days. Company insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of analyst reports. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and lifted their price target for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. The Goldman Sachs Group boosted their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the stock a “buy” rating in a research note on Wednesday, April 10th. Raymond James boosted their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a research note on Monday, January 8th. Finally, Royal Bank of Canada boosted their target price on Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research note on Thursday, February 1st. Five research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $604.69.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.